BIOVIE INC. - COMMON STOCK

BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo

06 3 2023 08:00:01 提供 Nasdaq GlobeNewswire

BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

02 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

BioVie Announces “BioVie Day” to be held March 23, 2023

21 2 2023 08:00:01 提供 Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

07 12 2022 08:00:01 提供 Nasdaq GlobeNewswire

BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

06 12 2022 06:00:00 提供 Nasdaq GlobeNewswire

BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

05 12 2022 17:00:00 提供 Nasdaq GlobeNewswire

BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients

29 11 2022 08:00:02 提供 Nasdaq GlobeNewswire

BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting

15 11 2022 08:00:01 提供 Nasdaq GlobeNewswire

BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

24 10 2022 08:00:03 提供 Nasdaq GlobeNewswire

BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

19 10 2022 06:00:00 提供 Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

04 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference

29 9 2022 08:00:01 提供 Nasdaq GlobeNewswire

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

07 9 2022 06:00:00 提供 Nasdaq GlobeNewswire

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

23 6 2022 08:00:02 提供 Nasdaq GlobeNewswire

BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference

25 4 2022 08:00:01 提供 Nasdaq GlobeNewswire

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

10 3 2022 08:00:01 提供 Nasdaq GlobeNewswire

BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

09 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

20 1 2022 08:00:02 提供 Nasdaq GlobeNewswire

BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

28 12 2021 08:00:00 提供 Nasdaq GlobeNewswire

BioVie Announces Partnership with the American Liver Foundation

09 12 2021 08:00:01 提供 Nasdaq GlobeNewswire